Editorial Desk 
The Anti-Counterfeit Authority – Kenya (ACA) and the Pharmacy and Poisons Board (PPB) have formalized a Memorandum of Understanding(MoU)to jointly combat the global challenge of counterfeit and illicit medicines.
This strategic partnership is a significant step towards enhancing public health safeguards.Counterfeit medicines not only impact market dynamics but also pose severe threats to consumer safety.
Dr. Robi M. N. King’a, PhD. ACA’s Executive Director, underscores the importance of upholding international property rights and protecting citizens from unsafe products.Recent data from the World Customs Organization and the International Institute for Research Against Counterfeit Medicines reveals a staggering 113 million illicit medicines valued at €52 million flagged in 2016 across 16 countries, including Kenya. This emphasizes the critical need for collaborative intervention.
The MoU establishes a framework for information exchange, training programs, expertise sharing, and outreach activities.Working committees will be formed to ensure meticulous planning, solidifying our commitment to a safer, healthier Kenya.
In 2008, the government enacted the Anti-Counterfeit Act that led to the institutionalization of the war against counterfeiting through the Anti-Counterfeit Agency that was later revealed into an Authority in 2018. In 2017, the Government established the Inter-Agency Anti-Illicit Trade Executive Forum and Technical Working Group (Multi-Agency Team for Combating Illicit Trade) to strengthen interventions toward curbing illicit trade and facilitate the exchange of information between agencies and enhance enforcement.
